Drug
Astragalus Polysaccharides 500 mg
Astragalus Polysaccharides 500 mg is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph not_applicable
1
20%
Ph phase_2
3
60%
Ph phase_4
1
20%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4
Trials by Phase
Phase 23 (60.0%)
Phase 41 (20.0%)
N/A1 (20.0%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
NCT01720563
completedphase_2
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
NCT03611712
completedphase_2
PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
NCT03314805
completedphase_4
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
NCT01720550
completednot_applicable
Effects of PG2 on Fatigue-Related Symptom Clusters
NCT02740959
Clinical Trials (5)
Showing 5 of 5 trials
NCT01720563Phase 2
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
NCT03611712Phase 2
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
NCT03314805Phase 2
PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
NCT01720550Phase 4
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
NCT02740959Not Applicable
Effects of PG2 on Fatigue-Related Symptom Clusters
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5